3 Reasons Why Gilead Sciences Stock Is a Buy Now
Gilead Sciences (NASDAQ: GILD) is a biotech behemoth, but its shares have fallen on tough times because hepatitis C sales are slipping. While headwinds in hepatitis C remain, the company's recent push into cancer treatment, best-in-class operating metrics, and cheap valuation make it a stock worth owning.
Make no mistake -- Gilead Sciences' decision to leapfrog to the forefront of oncology research by acquiring Kite Pharma is a big reason why this company's stock should be in your portfolio.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Amgen Inc. Stock
€293.30
2.000%
With 25 Buy predictions and not a single Sell prediction Amgen Inc. is an absolute favorite of our community.
As a result the target price of 298 € shows a slightly positive potential of 1.6% compared to the current price of 293.3 € for Amgen Inc..
